|Bid||40.46 x 800|
|Ask||40.53 x 900|
|Day's Range||39.23 - 40.56|
|52 Week Range||27.36 - 47.75|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.10|
Subscribe to Yahoo Finance Plus to view Fair Value for SAGE
CAMBRIDGE, Mass., September 19, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression. The 11 new analyses are being presented at the 2022 Psych Congress in New Orleans, September 17 to 20.
Sage Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
CAMBRIDGE, Mass., September 02, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 p.m. ET in New York, NY.